A dual antigen ELISA allows the assessment of SARS-CoV-2 antibody seroprevalence in a low transmission setting
dc.contributor.author | Hicks, S | |
dc.contributor.author | Pohl, K | |
dc.contributor.author | Neeman, T | |
dc.contributor.author | McNamara, H | |
dc.contributor.author | Parsons, K | |
dc.contributor.author | He, J-S | |
dc.contributor.author | Ali, S | |
dc.contributor.author | Nazir, S | |
dc.contributor.author | Rowntree, L | |
dc.contributor.author | Nguyen, T | |
dc.contributor.author | Kedzierska, K | |
dc.contributor.author | Doolan, D | |
dc.contributor.author | Vinueas, C | |
dc.contributor.author | Cook, M | |
dc.contributor.author | Coatsworth, N | |
dc.contributor.author | Myles, P | |
dc.contributor.author | Kurth, F | |
dc.contributor.author | Sander, L | |
dc.contributor.author | Mann, G | |
dc.contributor.author | Gruen, R | |
dc.contributor.author | George, A | |
dc.contributor.author | Gardiner, E | |
dc.contributor.author | Cockburn, I | |
dc.contributor.author | the SARS-CoV-2 Testing in Elective Surgery Collaborators | |
dc.date.accessioned | 2020-12-09T22:46:59Z | |
dc.date.available | 2020-12-09T22:46:59Z | |
dc.date.issued | 2020-09-14 | |
dc.identifier.citation | Hicks, S., Pohl, K., Neeman, T., McNamara, H., Parsons, K., He, J. -S., Ali, S., Nazir, S., Rowntree, L., Nguyen, T., Kedzierska, K., Doolan, D., Vinueas, C., Cook, M., Coatsworth, N., Myles, P., Kurth, F., Sander, L., Mann, G. ,... the SARS-CoV-2 Testing in Elective Surgery Collaborators (2020). A dual antigen ELISA allows the assessment of SARS-CoV-2 antibody seroprevalence in a low transmission setting. https://doi.org/10.1101/2020.09.09.20191031. | |
dc.identifier.uri | http://hdl.handle.net/11343/253073 | |
dc.description.abstract | Estimates of seroprevalence of SARS-CoV-2 antibodies have been hampered by inadequate assay sensitivity and specificity. Using an ELISA-based approach to that combines data about IgG responses to both the Nucleocapsid and Spike-receptor binding domain antigens, we show that near-optimal sensitivity and specificity can be achieved. We used this assay to assess the frequency of virus-specific antibodies in a cohort of elective surgery patients in Australia and estimated seroprevalence in Australia to be 0.28% (0 to 0.72%). These data confirm the low level of transmission of SARS-CoV-2 in Australia before July 2020 and validate the specificity of our assay. | |
dc.publisher | Cold Spring Harbor Laboratory | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
dc.title | A dual antigen ELISA allows the assessment of SARS-CoV-2 antibody seroprevalence in a low transmission setting | |
dc.type | Journal Article | |
dc.identifier.doi | 10.1101/2020.09.09.20191031 | |
melbourne.affiliation.department | Clinical Pathology | |
dc.rights.license | CC BY-NC-ND | |
melbourne.elementsid | 1467353 | |
melbourne.contributor.author | George, Amee | |
melbourne.accessrights | Open Access |